Skip to main content

The Weight of the Matter: Understanding the Science Behind Obesity and Weight Loss

Tracking # 20-1294799

$5.99

There are no ratings for this course

Learn more
Educator RXCE.COM
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

Obesity is a chronic and complex disease that requires a long-term, multifaceted approach to treatment. "Overweight" and "obese" statuses occur when the accumulation of excess fat increases the risk for a patient's poor health outcomes. Healthcare professionals assess a patient's weight circumference and/or body mass index (BMI) as estimates of body fat when diagnosing obesity. Obesity has been linked to numerous problematic health-related outcomes, including the development and worsening of diseases, increased healthcare costs, and diminished quality of life. Given its significant health impacts, patients should be encouraged to approach it as a lifelong condition requiring ongoing management rather than viewing weight loss as merely a short-term goal. Several factors, including genetics, behavior, socioeconomic conditions, and epigenetics, influence the pathophysiology of obesity. Understanding the underlying mechanisms of obesity is essential for healthcare professionals to develop effective treatment strategies and deliver patient-centered care. This course will describe the classification of obesity and explore its epidemiology, etiology, and pathophysiology, and learners will gain insight into the biological and environmental factors driving obesity. This educational activity will also emphasize the importance of a collaborative care approach to obesity management.

Subject areas

This course counts toward the state boards and subject areas below.

Florida Board of Pharmacy

Pharmacist

1.5h General

Michigan Board of Pharmacy

Pharmacist

1.5h General

Disclosure statements

The following individuals were involved in developing this activity: L. Austin Fredrickson, MD, FACP, Liz Fredrickson, PharmD, BCPS, Susan Bowlin,  DNP, FNP-BC, ACNP-BC, CBN, and Pamela Sardo, PharmD, BS. Austin Frederickson, Liz Frederickson, and Pamela Sardo have no conflict of interest or financial relationship or commercial or financial support relevant to this activity to report or disclose in the development of this activity. Susan Bowlin is a member of the Speaker’s Bureau for Eli Lilly and Novo Nordisk. Any potential conflicts of interest were mitigated.